Paediatric Abacavir/ Lamivudine/ Dolutegravir (pALD) Fixed-Dose Combination: Introduction and Rollout Planning Considerations for National Programmes

The resource, titled “”Paediatric Abacavir/Lamivudine/Dolutegravir (pALD) Fixed-Dose Combination: Introduction and Rollout Planning Considerations for National Programmes,”” focuses on the transition in HIV treatment for children. With the World Health Organization recommending Dolutegravir (DTG)-based regimens for children weighing at least 3 kg, the United States FDA tentatively approved paediatric DTG (pDTG) in 2020 for children weighing a minimum of 3 kg and at least four weeks old. As of the last quarter of 2022, at least 73 countries have ordered pDTG, and around 130,000 children have transitioned to this treatment. The brief aims to guide the transition from pDTG + abacavir/lamivudine (pABC/3TC) to the new fixed-dose combination dispersible tablet of paediatric ABC/3TC/DTG (pALD). Paediatric Abacavir/ Lamivudine/ Dolutegravir (pALD) Fixed-Dose Combination: Introduction and Rollout Planning Considerations for National Programmes